The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99-Reference-Cited by-同舟云学术

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99

Published:2004-03-24 Issue:7 Volume:2 Page:1047-1054
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

Darby S. C.,Keeling D. M.,Spooner R. J. D.,Wan Kan S.,Giangrande P. L. F.,Collins P. W.,Hill F. G. H.,Hay C. R. M.,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1538-7836.2004.00710.x/fullpdf

Reference27 articles.

1. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

3. Factor VIII and factor IX inhibitors in haemophiliacs;Ljung;Lancet,1992

4. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII;Addiego;Lancet,1993

5. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

Cited by 237 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern Treatment of Valvulopathies in Patients with Congenital Hemophilia;Life;2024-03-07

2. Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia A;Blood Advances;2024-03-01

3. Simoctocog alfa (Nuwiq^®) in children: early steps in life’s journey for people with severe hemophilia A;Therapeutic Advances in Hematology;2024-01

4. International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors;International Journal of Laboratory Hematology;2023-06-07

5. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial;Thrombosis and Haemostasis;2023-01